Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00221156
Status:
COMPLETED
Last Update Posted:
2009-06-25
First Post:
2005-09-13
Brief Title:
Acarbose and Secondary Prevention After Coronary Stenting
Sponsor:
Translational Research Center for Medical Innovation Kobe Hyogo Japan
Organization:
Translational Research Center for Medical Innovation Kobe Hyogo Japan
Study Overview
Official Title:
Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease ALERT Study
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether the intervention for newly diagnosed abnormal glucose tolerance after coronary stenting will improve the long-term clinical outcome
Detailed Description:
Recent studies have demonstrated that newly diagnosed abnormal glucose tolerance AGT diabetes mellitus and impaired glucose tolerance are common among the patients with ischemic heart disease Several large cohort studies indicate that people with prediabetic conditions such as impaired glucose tolerance have a raised risk of future cardiovascular disease Intervention with acarbose can prevent myocardial infarction and cardiovascular disease in type 2 diabetic and IGT patients However the effect of acarbose to secondary prevention of myocardial infarction or cardiovascular events in patients with newly diagnosed AGT after coronary stenting remains unclear The purpose of the present study is to determine whether the intervention to such abnormalities after coronary stenting will improve the long-term clinical outcome This is a opened randomized study to compare acarbose versus a standard lifestyle modification Patients will have a 11 chance of receiving acarbose versus the standard lifestyle modification There is some research evidence that suggests acarbose may improve clinical outcome in patients with type 2 diabetes and in IGT patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None